Spots Global Cancer Trial Database for Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
Official Title: A Phase 2 Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma Who Have Progressed Following Chemotherapy
Study ID: NCT05526989
Conditions
Study Description
Brief Summary: The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Moffitt Cancer Center, Tampa, Florida, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Jad Chahoud, MD, MPH
Affiliation: Moffitt Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
